Login / Signup

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.

Abdullah Salah AlanaziIsmaeel YunusaKhaled EleniziAbdulaziz Ibrahim Alzarea
Published in: Lung cancer management (2020)
In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient's individual clinical characteristics.
Keyphrases
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • tyrosine kinase
  • case report
  • palliative care
  • small cell lung cancer
  • combination therapy